[{"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":6174000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-278000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-6565000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-52369000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-27168000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-5313000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":678525.0,"OtherAssetsNoncurrent_0_Q2_USD":6161000.0,"Goodwill_0_Q2_USD":17260000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":24.39,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":-1808000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":-1008000.0,"ShareBasedCompensation_2_Q2_USD":4984000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":34527000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":18397000.0,"ProceedsFromNotesPayable_2_Q2_USD":9521000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":77000.0,"LongTermNotesPayable_0_Q2_USD":9400000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":152020000.0,"InterestIncomeExpenseNet_1_Q2_USD":-2388000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1912000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":232000.0,"IncreaseDecreaseInOtherNoncurrentAssets_2_Q2_USD":-171000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-385000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":20177000.0,"AmortizationOfFinancingCostsAndDiscounts_2_Q2_USD":27000.0,"AccretionExpense_2_Q2_USD":4385000.0,"OperatingIncomeLoss_2_Q2_USD":-47765000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-93000.0,"AccountsPayableTradeCurrent_0_Q2_USD":4734000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":4984000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":2603000.0,"OtherLiabilitiesCurrent_0_Q2_USD":732000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":-278000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-6565000.0,"InterestIncomeExpenseNet_2_Q2_USD":-4326000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":3916000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":3461000.0,"OperatingIncomeLoss_1_Q2_USD":-18215000.0,"OperatingExpenses_1_Q2_USD":20127000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":184005000.0,"Liabilities_0_Q2_USD":94885000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":5000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":16627000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":8474000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-3.58,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.38,"CommonStockValue_0_Q2_USD":149000.0,"CommonStockSharesOutstanding_0_Q2_shares":14989021.0,"CommonStockSharesIssued_0_Q2_shares":14989021.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":152020000.0,"AssetsCurrent_0_Q2_USD":159987000.0,"Assets_0_Q2_USD":184005000.0,"AdditionalPaidInCapital_0_Q2_USD":294075000.0,"LiabilitiesCurrent_0_Q2_USD":17218000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":67502000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-78000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-46862000.0,"CommonStockSharesAuthorized_0_Q2_shares":30000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.01,"AccruedLiabilitiesCurrent_0_Q2_USD":11752000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":14556986.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":14981756.0,"StockholdersEquity_0_Q2_USD":89120000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-211278000.0,"OperatingExpenses_2_Q2_USD":51226000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":597000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":42999000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":7967000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":78000.0,"OtherOperatingIncomeExpenseNet_2_Q2_USD":-72000.0,"OtherOperatingIncomeExpenseNet_1_Q2_USD":6744000.0,"NetIncomeLoss_1_Q2_USD":-20603000.0,"NetIncomeLoss_2_Q2_USD":-52091000.0,"ProfitLoss_2_Q2_USD":-52091000.0,"StockIssuedDuringPeriodValueShareBasedCompensationGross_1_Q2_USD":2603000.0,"Ticker":"ALBO","CIK":"1322505","name":"ALBIREO PHARMA, INC.","OfficialName":"Albireo Pharma Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688702712.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]